FDA approves Empliciti® (elotuzumab) as a treatment for myeloma

Bristol-Myers Squibb and AbbVie have announced that the US Food and Drug Administration (FDA) has approved the use of Empliciti in combination with Revlimid® and dexamethasone (ERd) as a treatment for relapsed myeloma patients who have received between one to three previous lines of treatment. The approval is based on data from the Phase III ELOQUENT-2…

Details